Catherine S. Pinal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catherine S. Pinal has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Peter Gluckman
University of Auckland
5 shared publications - Mark A. Hanson
Institute of Developmental Sciences, University of Southampton, Southampton, UK
2 shared publications Michael J. Soares
Department of Physiology, Ralph L. Smith Mental Retardation Research Center, University of Kansas Medical Center, Kansas City 66103
2 shared publicationsA J Tobin
1 shared publication- Alistair Jan Gunn
University of Auckland
1 shared publication Allan J. Tobin
Departments of a Biology, b Physiological Science, and c Neurology,d 11 Molecular Biology Institute, and e Brain Research Institute, University of California, Los Angeles, Calif., USA
1 shared publication
Latest Publications
- 28 June 2005
- Published by Wiley in Maternal & Child Nutrition
- Vol. 1 (3) , 130-141
The developmental origins of adult disease
Epidemiological and clinical observations have led to the hypothesis that the risk of developing some chronic diseases in adulthood is influenced not only by genetic and adult lifestyle factors, but also by environmental factors acting in early life. These factors act through the processes of developmental plasticity and possibly epigenetic modification, and can be distinguished from developmental disruption. The concept of predictive adaptation has been developed to explain the relationship between early life events and the risk of later disease. At its base, the model suggests that a mismatch between fetal expectation of its postnatal environment and actual postnatal environment contribute to later adult disease risk. This mismatch is exacerbated, in part, by the phenomenon of ‘maternal constraint’ on fetal growth, which implicitly provides an upper limit of postnatal nutritional environment that humans have adapted for and is now frequently exceeded. These experimental, clinical and conceptual considerations have important implications for prevention and intervention in the current epidemic of childhood obesity and adult metabolic and cardiovascular disorders.
- 28 June 2005
- Published by Wiley in Maternal & Child Nutrition
- Vol. 1 (3) , 130-141
The developmental origins of adult disease
Epidemiological and clinical observations have led to the hypothesis that the risk of developing some chronic diseases in adulthood is influenced not only by genetic and adult lifestyle factors, but also by environmental factors acting in early life. These factors act through the processes of developmental plasticity and possibly epigenetic modification, and can be distinguished from developmental disruption. The concept of predictive adaptation has been developed to explain the relationship between early life events and the risk of later disease. At its base, the model suggests that a mismatch between fetal expectation of its postnatal environment and actual postnatal environment contribute to later adult disease risk. This mismatch is exacerbated, in part, by the phenomenon of ‘maternal constraint’ on fetal growth, which implicitly provides an upper limit of postnatal nutritional environment that humans have adapted for and is now frequently exceeded. These experimental, clinical and conceptual considerations have important implications for prevention and intervention in the current epidemic of childhood obesity and adult metabolic and cardiovascular disorders.
- 1 February 2005
- Published by S. Karger AG in Neonatology
- Vol. 87 (2) , 127-139
Life-Long Echoes – A Critical Analysis of the Developmental Origins of Adult Disease Model
The hypothesis that there is a developmental component to subsequent adult disease initially arose from epidemiological findings relating birth size to either indices of disease risk or actual disease prevalence in later life. While components of the epidemiological analyses have been challenged, there is strong evidence that developmental factors contribute to the later risk of metabolic disease – including insulin resistance, obesity, and heart disease – as well as have a broader impact on osteoporosis, depression and schizophrenia. We suggest that disease risk is greater when there is a mismatch between the early developmental environment (i.e., the phase of developmental plasticity) versus that experienced in mature life (i.e., adulthood), and that nutritional influences are particularly important. It is also critical to distinguish between those factors acting during the developmental phase that disrupt development from those influences that are less extreme and act through regulated processes of epigenetic change. A modelof the relationship between the developmental and mature environment is proposed and suggests interventional strategies that will vary in different population settings.
- 1 February 2005
- Published by S. Karger AG in Neonatology
- Vol. 87 (2) , 127-139
Life-Long Echoes – A Critical Analysis of the Developmental Origins of Adult Disease Model
The hypothesis that there is a developmental component to subsequent adult disease initially arose from epidemiological findings relating birth size to either indices of disease risk or actual disease prevalence in later life. While components of the epidemiological analyses have been challenged, there is strong evidence that developmental factors contribute to the later risk of metabolic disease – including insulin resistance, obesity, and heart disease – as well as have a broader impact on osteoporosis, depression and schizophrenia. We suggest that disease risk is greater when there is a mismatch between the early developmental environment (i.e., the phase of developmental plasticity) versus that experienced in mature life (i.e., adulthood), and that nutritional influences are particularly important. It is also critical to distinguish between those factors acting during the developmental phase that disrupt development from those influences that are less extreme and act through regulated processes of epigenetic change. A modelof the relationship between the developmental and mature environment is proposed and suggests interventional strategies that will vary in different population settings.
- Open Access
- 1 May 2003
- Published by Elsevier in The Journal of Nutrition
- Vol. 133 (5) , 1741S-1746S
Regulation of Fetal Growth by the Somatotrophic Axis
Suboptimal fetal growth is associated with higher fetal mortality and with higher neonatal morbidity and mortality. It increases the likelihood of premature birth that in turn further compounds perinatal health risks. Moreover, an abnormal fetal environment, as reflected in an altered birth size phenotype, increases the propensity for disease in childhood and adulthood. Fetal growth represents the culmination of interaction between the fetal genome and the in utero environment determined by maternal-placental function. The role of endocrine and metabolic factors in mediating this interaction will be reviewed. There is also evidence that fetal growth, as measured in late gestation, is dependent not only on the maternal environment but on events that occurred during the periconceptual period. Thus, fetal growth not only reflects the immediate fetal environment but events surrounding conception and embryonic life.
- 1 May 2003
- Published by Elsevier in The Journal of Nutrition
- Vol. 133 (5) , 1741S-1746S
Open AccessRegulation of Fetal Growth by the Somatotrophic Axis
Suboptimal fetal growth is associated with higher fetal mortality and with higher neonatal morbidity and mortality. It increases the likelihood of premature birth that in turn further compounds perinatal health risks. Moreover, an abnormal fetal environment, as reflected in an altered birth size phenotype, increases the propensity for disease in childhood and adulthood. Fetal growth represents the culmination of interaction between the fetal genome and the in utero environment determined by maternal-placental function. The role of endocrine and metabolic factors in mediating this interaction will be reviewed. There is also evidence that fetal growth, as measured in late gestation, is dependent not only on the maternal environment but on events that occurred during the periconceptual period. Thus, fetal growth not only reflects the immediate fetal environment but events surrounding conception and embryonic life.
- 1 January 2002
- Published by Springer Nature in Endocrine
- Vol. 19 (1) , 81-90
Maternal-Placental-Fetal Interactions in the Endocrine Regulation of Fetal Growth : Role of Somatotrophic Axes
Inadequate growth in utero is associated not only with adverse fetal, perinatal, and neonatal outcomes, but also with an altered propensity for disease later in life. Conversely, fetal overgrowth is also associated with increased medical risks for both mother and fetus. The interaction between the fetal genome and the intrauterine environment determines in great part how fetal growth will progress. The placental, maternal, and fetal somatotrophic axes (growth hormone/insulin-like growth factor-1) play key roles in modulating this interaction. Experimental undernutrition in animal models has numerous effects over these axes and provides insight into understanding fetal growth and its abnormalities. This review addresses the contributions made by the placental, maternal, and fetal somatotrophic axes to the regulation of fetal growth.
- 1 January 2002
- Published by Springer Nature in Endocrine
- Vol. 19 (1) , 81-90
Maternal-Placental-Fetal Interactions in the Endocrine Regulation of Fetal Growth : Role of Somatotrophic Axes
Inadequate growth in utero is associated not only with adverse fetal, perinatal, and neonatal outcomes, but also with an altered propensity for disease later in life. Conversely, fetal overgrowth is also associated with increased medical risks for both mother and fetus. The interaction between the fetal genome and the intrauterine environment determines in great part how fetal growth will progress. The placental, maternal, and fetal somatotrophic axes (growth hormone/insulin-like growth factor-1) play key roles in modulating this interaction. Experimental undernutrition in animal models has numerous effects over these axes and provides insight into understanding fetal growth and its abnormalities. This review addresses the contributions made by the placental, maternal, and fetal somatotrophic axes to the regulation of fetal growth.
- 1 April 2001
- Published by Elsevier in Seminars in Neonatology
- Vol. 6 (2) , 109-120
Hypoxic-ischemic brain injury in the newborn: pathophysiology and potential strategies for intervention
- 1 April 2001
- Published by Elsevier in Seminars in Neonatology
- Vol. 6 (2) , 109-120
Hypoxic-ischemic brain injury in the newborn: pathophysiology and potential strategies for intervention
- 1 January 1998
- Vol. 5, 109-18
Uniqueness and redundancy in GABA production.
GABA is present in organisms belonging to at least four of the five kingdoms. It acts as a neurotransmitter, a paracrine signaling molecule, a metabolic intermediate, or a trophic factor. In mammals, GABA synthesis depends on two forms of the enzyme glutamic acid decarboxylase--GAD65 and GAD67--that may serve distinctive functions within GABA-producing cells. The two GADs derive from two genes, which are differentially regulated, though nearly every GABA-producing cell contains both forms of GAD. GAD67 predominates early in development and after neuronal injury, consistent with a possible role in producing GABA for trophic use. In the embryo, GAD67 transcripts also undergo alternative splicing, which gives rise to truncated forms. In the mature neuron, GAD67 is present in both terminals and the cell body, where it may subserve a nonsynaptic, intracellular GABA pool. In contrast, GAD65 is usually expressed later in development and is primarily localized to nerve terminals. GAD65 enzymatic activity is more subject to regulation by cofactor binding and neuronal activity, consistent with its involvement in the production of synaptic GABA. Thus, while both GAD67 and GAD65 mediate the synthesis of GABA, their unique distributions and expression patterns suggest divergent functional roles.
- 1 January 1998
- Vol. 5, 109-18
Uniqueness and redundancy in GABA production.
GABA is present in organisms belonging to at least four of the five kingdoms. It acts as a neurotransmitter, a paracrine signaling molecule, a metabolic intermediate, or a trophic factor. In mammals, GABA synthesis depends on two forms of the enzyme glutamic acid decarboxylase--GAD65 and GAD67--that may serve distinctive functions within GABA-producing cells. The two GADs derive from two genes, which are differentially regulated, though nearly every GABA-producing cell contains both forms of GAD. GAD67 predominates early in development and after neuronal injury, consistent with a possible role in producing GABA for trophic use. In the embryo, GAD67 transcripts also undergo alternative splicing, which gives rise to truncated forms. In the mature neuron, GAD67 is present in both terminals and the cell body, where it may subserve a nonsynaptic, intracellular GABA pool. In contrast, GAD65 is usually expressed later in development and is primarily localized to nerve terminals. GAD65 enzymatic activity is more subject to regulation by cofactor binding and neuronal activity, consistent with its involvement in the production of synaptic GABA. Thus, while both GAD67 and GAD65 mediate the synthesis of GABA, their unique distributions and expression patterns suggest divergent functional roles.
- 12 December 1997
- Published by S. Karger AG in Developmental Neuroscience
- Vol. 19 (6) , 465-475
Multiple Elements Regulate GAD 65 Transcription
GAD65 and GAD67, the two forms of GABA-synthesizing enzyme, are usually coexpressed, but their levels are regulated independently. The GAD67 promoter has been described. We have now characterized transcriptional regulatory elements in the 5'' flanking region of the GAD65 gene, extending 2.4 kb from the ATG translation initiation site. Primer extension assays revealed that transcription begins at –228 in both adult rat brain and in P19 embryonal carcinoma cells, with additional start sites at –280 in brain and at –360 in P19 cells. These sites are in a GC-rich (72%) region lacking a TATA box. Transient transfection assays revealed that the basal promoter is between –740 and –60, and elements conferring cell-type specificity are further 5''. DNA sequences between –1652 and –1420 can ''silence'' transcription from a heterologous promoter. GAD65 and GAD67 promoters share little sequence identity, consistent with differences in their transcriptional regulation.
- 12 December 1997
- Published by S. Karger AG in Developmental Neuroscience
- Vol. 19 (6) , 465-475
Multiple Elements Regulate GAD 65 Transcription
GAD65 and GAD67, the two forms of GABA-synthesizing enzyme, are usually coexpressed, but their levels are regulated independently. The GAD67 promoter has been described. We have now characterized transcriptional regulatory elements in the 5'' flanking region of the GAD65 gene, extending 2.4 kb from the ATG translation initiation site. Primer extension assays revealed that transcription begins at –228 in both adult rat brain and in P19 embryonal carcinoma cells, with additional start sites at –280 in brain and at –360 in P19 cells. These sites are in a GC-rich (72%) region lacking a TATA box. Transient transfection assays revealed that the basal promoter is between –740 and –60, and elements conferring cell-type specificity are further 5''. DNA sequences between –1652 and –1420 can ''silence'' transcription from a heterologous promoter. GAD65 and GAD67 promoters share little sequence identity, consistent with differences in their transcriptional regulation.
- 1 February 1989
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 40 (2) , 435-447
Cyclic Adenosine 3′,5′-Monophosphate Analogues Modulate Rat Placental Cell Growth and Differentiation1
Cyclic adenosine 3',5'-monophosphate (cAMP) has been implicated in the control of placental function. The present investigation was designed to evaluate the actions of cAMP analogues on the control of rat placental development. Two model systems were used to assess the actions of cAMP in the placenta: 1) a rat placental cell line and 2) rat labyrinth placental explants. Elevation of intracellular cAMP via treatment with cAMP analogues, 3-isobutyl-1-methylxanthine, forskolin, or cholera toxin inhibited placental cell DNA synthesis whereas treatment with an analogue to cyclic guanosine 3',5'-monophosphate was without effect. The inhibitory actions of dibutyryl cAMP on DNA synthesis were at least partially reversible and were not the result of metabolic toxicity. Dibutyryl cAMP had dramatic effects on the organization and morphology of placental cells growing in vitro and diminished the ability of the placental cells to grow following transplantation into allogeneic hosts. Differentiation-associated characteristics of rat placental cells were also affected by cAMP. cAMP analogues stimulated placental cell progesterone release and inhibited placental cell alkaline phosphatase activity. Dibutyryl cAMP had effects on placental labyrinth explants similar to its effects on the placental cell line. Dibutyryl cAMP inhibited explant outgrowth while stimulating explant release of progesterone. In summary, cAMP effectively modulates the growth and differentiation of rat placental cells in vitro.
- 1 February 1989
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 40 (2) , 435-447
Cyclic Adenosine 3′,5′-Monophosphate Analogues Modulate Rat Placental Cell Growth and Differentiation1
Cyclic adenosine 3',5'-monophosphate (cAMP) has been implicated in the control of placental function. The present investigation was designed to evaluate the actions of cAMP analogues on the control of rat placental development. Two model systems were used to assess the actions of cAMP in the placenta: 1) a rat placental cell line and 2) rat labyrinth placental explants. Elevation of intracellular cAMP via treatment with cAMP analogues, 3-isobutyl-1-methylxanthine, forskolin, or cholera toxin inhibited placental cell DNA synthesis whereas treatment with an analogue to cyclic guanosine 3',5'-monophosphate was without effect. The inhibitory actions of dibutyryl cAMP on DNA synthesis were at least partially reversible and were not the result of metabolic toxicity. Dibutyryl cAMP had dramatic effects on the organization and morphology of placental cells growing in vitro and diminished the ability of the placental cells to grow following transplantation into allogeneic hosts. Differentiation-associated characteristics of rat placental cells were also affected by cAMP. cAMP analogues stimulated placental cell progesterone release and inhibited placental cell alkaline phosphatase activity. Dibutyryl cAMP had effects on placental labyrinth explants similar to its effects on the placental cell line. Dibutyryl cAMP inhibited explant outgrowth while stimulating explant release of progesterone. In summary, cAMP effectively modulates the growth and differentiation of rat placental cells in vitro.
- 1 November 1987
- Published by Elsevier in Developmental Biology
- Vol. 124 (1) , 134-144
Establishment of a rat placental cell line expressing characteristics of extraembryonic membranes
- 1 November 1987
- Published by Elsevier in Developmental Biology
- Vol. 124 (1) , 134-144
Establishment of a rat placental cell line expressing characteristics of extraembryonic membranes